Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC(RASolve 308) | recruiting | Phase 3 | 430 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT05317858 | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets(LIMITLESS) | recruiting | Phase 3 | 30 | InSightecINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07109531 | ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy | recruiting | Phase 3 | 286 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | recruiting | Phase 3 | 474 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06500481 | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04853342 | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy(FORWARD) | recruiting | Phase 3 | 318 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation | recruiting | Phase 3 | 392 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation | recruiting | Phase 3 | 300 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07251582 | Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer(LungTime-C02) | recruiting | Phase 3 | 186 | Hunan Province Tumor HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07668752 | A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation | recruiting | Phase 3 | 300 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) | recruiting | Phase 2 / Phase 3 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06472245 | Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor(ARTEMIA) | recruiting | Phase 3 | 363 | OSE ImmunotherapeuticsINDUSTRY | 14 | Jul 23, 2026 | clinicaltrials |
| NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 / Phase 3 | 230 | Swiss Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06686771 | Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer(CURB2) | recruiting | Phase 3 | 320 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | recruiting | Phase 3 | 574 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06927986 | Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） | recruiting | Phase 3 | 380 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT07131319 | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | recruiting | Phase 2 / Phase 3 | 30 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)(LuTK03) | recruiting | Phase 3 | 500 | Candel Therapeutics, Inc.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07416994 | Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 3 | 440 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | recruiting | Phase 3 | 180 | Nuvation Bio Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 10,000 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.(ARIAN) | recruiting | Phase 3 | 129 | Fundación GECPOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06486142 | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study(ERIS) | recruiting | Phase 3 | 200 | Region SkaneOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06437977 | Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)(neoR-TORCH) | recruiting | Phase 3 | 478 | Shanghai Chest HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06616584 | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | recruiting | Phase 2 / Phase 3 | 378 | SWOG Cancer Research NetworkNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT04585490 | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | recruiting | Phase 3 | 48 | Maximilian DiehnOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06930794 | A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive(KUNPENG-3) | recruiting | Phase 3 | 300 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT06838273 | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) | recruiting | Phase 3 | 720 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT06141070 | Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease(ANDROMEDA) | recruiting | Phase 3 | 240 | Vastra Gotaland RegionOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | recruiting | Phase 3 | 194 | Nuvation Bio Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05445791 | Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations(METLUNG) | recruiting | Phase 3 | 312 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05852990 | Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC | recruiting | Phase 3 | 28 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06928389 | Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer(NSCLC) | recruiting | Phase 3 | 536 | AkesoINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06545747 | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI | recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06840704 | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer(Relief) | recruiting | Phase 3 | 121 | Hunan Cancer HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06123754 | Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC | recruiting | Phase 3 | 390 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07174908 | A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | recruiting | Phase 3 | 400 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma(CRYOMUNE) | recruiting | Phase 3 | 214 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | recruiting | Phase 3 | 246 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | recruiting | Phase 3 | 300 | Maia BiotechnologyINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials